Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius（2696.HK）announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaled RMB407.8 million, attributed to the highly efficient commercial operation and successive growth in core products. Among which, HANQUYOU...

Related Keywords

Songjiang ,Jilin ,China ,Cintas ,Bahia ,Brazil ,Switzerland ,Singapore ,United Kingdom ,Shanghai ,Canada ,Netherlands ,Argentina ,Indonesia ,India ,Australia ,Xuhui ,United States ,Saudi Arabia ,Chinese ,America ,Jason Zhu ,Wenjie Zhang ,European Society Of Medical Oncology ,National Medical Products Administration ,European Union ,Health Canada ,Drug Administration ,Executive Director ,Chief Executive Officer ,Chief Financial Officer ,New Drug Submission ,New Drug Application ,North African ,Medical Oncology ,Songjiang Second Plant ,Xuhui Facility ,Songjiang First Plant ,Pre License Inspection ,Youth Care Inspectorate ,Good Manufacturing Practice ,Xuhui Plant ,